Eaton Vance Management’s Transmedics TMDX Stock Holding History

Eaton Vance Management’s Portfolio TMDX Stock Details TMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,300	Closed	-$25K	–	2639
2021 Q4	$25K	Hold	1,300	–	–	﹤0.01%	2345
2021 Q3	$43K	Hold	1,300	–	–	﹤0.01%	1544
2021 Q2	$43K	Hold	1,300	–	–	﹤0.01%	2211
2021 Q1	$54K	Buy	+1,300	New	+$40K	﹤0.01%	1778

Other funds holding TMDX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

SCP

Sandhill Capital Partners Buffalo, New York $1.23B AUM 13.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

KCM

Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return

Eaton Vance Management's TMDX Position: Q1 2022 in Review

Eaton Vance Management sold out of Transmedics (TMDX) in Q1 2022, closing a stake of 1,300 shares — an estimated $25K sold.

Eaton Vance Management first reported a position in TMDX in Q1 2021 and held it in 4 quarters. The position peaked at $54K in Q1 2021. 110 funds tracked by Wall St. Rank hold TMDX as of Q1 2022.

Eaton Vance Management reported no remaining Transmedics position as of Q1 2022 after selling out during the quarter.
Eaton Vance Management sold 1,300 Transmedics shares in Q1 2022, an estimated $25K.
Eaton Vance Management first reported a position in Transmedics in Q1 2021 and held it in 4 quarters.
Eaton Vance Management's Transmedics position peaked at $54K in Q1 2021.
110 funds tracked by Wall St. Rank held Transmedics as of Q1 2022.

Based on Eaton Vance Management's 13F filing for Q1 2022, filed 16 May 2022.